Neuronetics Management
Management criteria checks 2/4
Neuronetics' CEO is Keith Sullivan, appointed in Jul 2020, has a tenure of 5.5 years. total yearly compensation is $2.43M, comprised of 30% salary and 70% bonuses, including company stock and options. directly owns 1.37% of the company’s shares, worth $1.84M. The average tenure of the management team and the board of directors is 1 years and 4.8 years respectively.
Key information
Keith Sullivan
Chief executive officer
US$2.4m
Total compensation
| CEO salary percentage | 29.95% |
| CEO tenure | 5.5yrs |
| CEO ownership | 1.4% |
| Management average tenure | 1yr |
| Board average tenure | 4.8yrs |
Recent management updates
Why We Think Neuronetics, Inc.'s (NASDAQ:STIM) CEO Compensation Is Not Excessive At All
May 15
Here's Why Shareholders May Want To Be Cautious With Increasing Neuronetics, Inc.'s (NASDAQ:STIM) CEO Pay Packet
May 24Recent updates
There's No Escaping Neuronetics, Inc.'s (NASDAQ:STIM) Muted Revenues Despite A 25% Share Price Rise
Jan 07Would Neuronetics (NASDAQ:STIM) Be Better Off With Less Debt?
Dec 13Slammed 29% Neuronetics, Inc. (NASDAQ:STIM) Screens Well Here But There Might Be A Catch
Nov 14The Neuronetics, Inc. (NASDAQ:STIM) Third-Quarter Results Are Out And Analysts Have Published New Forecasts
Nov 06Market Cool On Neuronetics, Inc.'s (NASDAQ:STIM) Revenues Pushing Shares 29% Lower
Aug 26Here's What Analysts Are Forecasting For Neuronetics, Inc. (NASDAQ:STIM) After Its Second-Quarter Results
Aug 07Why We Think Neuronetics, Inc.'s (NASDAQ:STIM) CEO Compensation Is Not Excessive At All
May 15Neuronetics, Inc. (NASDAQ:STIM) Just Reported And Analysts Have Been Lifting Their Price Targets
May 09Neuronetics, Inc.'s (NASDAQ:STIM) 30% Jump Shows Its Popularity With Investors
May 04
TMS Acquisition And BMP Expansion Will Transform Treatment Delivery
The acquisition of Greenbrook and expansion of the BMP program are expected to significantly boost revenue through increased patient access and operational efficiency.Neuronetics: Explosive Growth Poised To Soar On FDA Breakthroughs
Mar 30Neuronetics, Inc.'s (NASDAQ:STIM) Shares Leap 69% Yet They're Still Not Telling The Full Story
Mar 06Industry Analysts Just Made A Dazzling Upgrade To Their Neuronetics, Inc. (NASDAQ:STIM) Revenue Forecasts
Feb 10Neuronetics, Inc.'s (NASDAQ:STIM) Shares Leap 43% Yet They're Still Not Telling The Full Story
Jan 11Neuronetics (NASDAQ:STIM) Is Making Moderate Use Of Debt
Jan 02Neuronetics, Inc. (NASDAQ:STIM) Analysts Just Slashed Next Year's Revenue Estimates By 12%
Nov 18A Piece Of The Puzzle Missing From Neuronetics, Inc.'s (NASDAQ:STIM) 28% Share Price Climb
Nov 05Investors Give Neuronetics, Inc. (NASDAQ:STIM) Shares A 60% Hiding
Aug 13Here's Why Shareholders May Want To Be Cautious With Increasing Neuronetics, Inc.'s (NASDAQ:STIM) CEO Pay Packet
May 24The Neuronetics, Inc. (NASDAQ:STIM) First-Quarter Results Are Out And Analysts Have Published New Forecasts
May 09Neuronetics: Reality Set In
May 09Market Cool On Neuronetics, Inc.'s (NASDAQ:STIM) Revenues Pushing Shares 36% Lower
May 08Neuronetics (NASDAQ:STIM) Has Debt But No Earnings; Should You Worry?
May 01Even With A 26% Surge, Cautious Investors Are Not Rewarding Neuronetics, Inc.'s (NASDAQ:STIM) Performance Completely
Mar 17Neuronetics: Modest Improvements Are Not Enough
Jan 30Neuronetics, Inc. (NASDAQ:STIM) Soars 61% But It's A Story Of Risk Vs Reward
Dec 19Neuronetics, Inc.'s (NASDAQ:STIM) Shares Not Telling The Full Story
Jun 21Does Neuronetics (NASDAQ:STIM) Have A Healthy Balance Sheet?
May 10CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2025 | n/a | n/a | -US$45m |
| Jun 30 2025 | n/a | n/a | -US$49m |
| Mar 31 2025 | n/a | n/a | -US$49m |
| Dec 31 2024 | US$2m | US$728k | -US$44m |
| Sep 30 2024 | n/a | n/a | -US$36m |
| Jun 30 2024 | n/a | n/a | -US$32m |
| Mar 31 2024 | n/a | n/a | -US$28m |
| Dec 31 2023 | US$3m | US$700k | -US$30m |
| Sep 30 2023 | n/a | n/a | -US$33m |
| Jun 30 2023 | n/a | n/a | -US$31m |
| Mar 31 2023 | n/a | n/a | -US$37m |
| Dec 31 2022 | US$2m | US$676k | -US$37m |
| Sep 30 2022 | n/a | n/a | -US$37m |
| Jun 30 2022 | n/a | n/a | -US$37m |
| Mar 31 2022 | n/a | n/a | -US$34m |
| Dec 31 2021 | US$3m | US$650k | -US$31m |
| Sep 30 2021 | n/a | n/a | -US$27m |
| Jun 30 2021 | n/a | n/a | -US$22m |
| Mar 31 2021 | n/a | n/a | -US$23m |
| Dec 31 2020 | US$4m | US$280k | -US$27m |
Compensation vs Market: Keith's total compensation ($USD2.43M) is above average for companies of similar size in the US market ($USD573.27K).
Compensation vs Earnings: Keith's compensation has been consistent with company performance over the past year.
CEO
Keith Sullivan (67 yo)
Mr. Keith J. Sullivan has been President, Chief Executive Officer and Director of Neuronetics, Inc. since July 14, 2020. Mr. Sullivan has been a Director of Venus Concept Inc. (formerly known as Restoratio...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 5.5yrs | US$2.43m | 1.37% $ 1.8m | |
| EVP, Chief Legal Officer & Corporate Secretary | 6yrs | US$1.06m | 0.39% $ 527.8k | |
| Senior Advisor to the CEO | less than a year | US$1.18m | 0.21% $ 279.4k | |
| Executive VP | less than a year | no data | no data | |
| Senior VP & Chief of Operations | 1yr | no data | no data | |
| SVP & Chief Technology Officer | 1yr | no data | no data | |
| Senior VP & Chief Marketing Officer | 2.7yrs | no data | no data | |
| Senior VP & Chief Revenue Officer | 2.9yrs | no data | no data | |
| Chief Clinic Officer | 1yr | no data | no data |
Experienced Management: STIM's management team is not considered experienced ( 1 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 5.5yrs | US$2.43m | 1.37% $ 1.8m | |
| Independent Director | 8.5yrs | US$132.92k | 0.50% $ 670.0k | |
| Independent Director | 6.3yrs | US$128.33k | 0.28% $ 375.8k | |
| Independent Chairman of the Board | 4.8yrs | US$255.21k | 0.81% $ 1.1m | |
| Independent Director | 1.1yrs | US$14.25k | 0.018% $ 24.5k | |
| Independent Director | 1.1yrs | US$17.57k | 2.17% $ 2.9m | |
| Independent Director | 4.4yrs | US$121.67k | 0.13% $ 168.3k |
Experienced Board: STIM's board of directors are considered experienced (4.8 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/01/09 13:25 |
| End of Day Share Price | 2026/01/09 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Neuronetics, Inc. is covered by 4 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| William Plovanic | Canaccord Genuity |
| David Turkaly | Citizens JMP Securities, LLC |
| Daniel Stauder | Citizens JMP Securities, LLC |